Related Experiment Video
Updated: Oct 11, 2025
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Bayesian network meta-analysis comparing cryoablation, radiofrequency ablation, and antiarrhythmic drugs as initial
Mahmoud Elsayed1, Omar M Abdelfattah2, Ahmed Sayed3
1Department of Cardiovascular Medicine, Cardiovascular Institute at Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
Background:
Antiarrhythmic drugs (AADs) and catheter ablation are first line treatments of paroxysmal atrial fibrillation (PAF), however, there exists a paucity of data regarding the potential benefit of different catheter ablation technologies versus AADs as an early rhythm strategy.
Objective:
To assess the safety and efficacy of cryoablation versus radiofrequency ablation (RFA) versus AADs as a first line therapy of PAF.
Methods:
MEDLINE, Embase, Scopus and CENTRAL were searched to retrieve randomized clinical trials (RCTs) comparing cryoablation, RFA or AADs to one another as first line therapies for atrial fibrillation (AF). The primary outcome was overall freedom from arrhythmia recurrence (AF, atrial flutter [AFL], atrial tachycardia). Secondary outcomes included freedom from symptomatic arrhythmia recurrence, hospitalization, and serious adverse events. A random-effects Bayesian network meta-analysis was used to calculate odds ratios (OR) and 95% credible intervals (CrI).
Results:
Six RCTs (N = 1212) met the inclusion criteria (605 AADs, 365 Cryoablation, and 245 RFA). Compared with AADs, overall recurrence was reduced with RFA (OR: 0.31; 95% CrI: 0.10-0.71) and cryoablation (OR: 0.39; 95% CrI: 0.16-1.00). Comparing ablation (cryoablation and RFA) with AADs in respect to freedom from symptomatic AF recurrence, neither cryoablation (OR: 0.35; 95% CrI: 0.06-1.96) nor RFA (OR: 0.34; 95% CrI: 0.07-1.27) resulted in statistically significant reductions individually compared to AADs, though pooled ablation with both technologies showed lower odds of arrhythmia recurrence (OR: 0.35; 95% CrI: 0.13-0.79). In terms of serious adverse events rates, neither cryoablation (OR: 0.77; 95% CrI: 0.44-1.39) nor RFA (OR: 1.45; 95% CrI: 0.67-3.23) were significantly different to AADs. RFA resulted in a statistically significant reduction in hospitalizations compared to AAD (OR: 0.08; 95% CrI: 0.01-0.99), whereas cryoablation did not (OR: 0.77; 95% CrI: 0.44-1.39). The surface under the cumulative ranking curve showed RFA to be the most effective treatment at reducing overall rates of recurrence, symptomatic recurrence and hospitalizations; whereas cryoablation was most likely to reduce serious adverse events.
Conclusion:
Cryoablation and RFA are both effective and safe first line therapies for AF compared to AADs, with RFA being the most effective at reducing recurrences.
Insights
Radiofrequency ablation (RFA) and cryoablation are effective first-line treatments for paroxysmal atrial fibrillation (PAF) compared to antiarrhythmic drugs (AADs). RFA demonstrates superior efficacy in reducing arrhythmia recurrence and hospitalizations.
Area of Science:
- Cardiology
- Medical Technology
- Clinical Trials
Background:
- Paroxysmal atrial fibrillation (PAF) is commonly treated with antiarrhythmic drugs (AADs) or catheter ablation.
- Limited data exists comparing the efficacy of different catheter ablation technologies against AADs as an early rhythm control strategy.
Purpose of the Study:
- To evaluate the safety and effectiveness of cryoablation and radiofrequency ablation (RFA) compared to AADs as a primary treatment for PAF.
Main Methods:
- A systematic literature search was conducted across MEDLINE, Embase, Scopus, and CENTRAL for randomized clinical trials (RCTs).
- Bayesian network meta-analysis was employed to compare cryoablation, RFA, and AADs, assessing overall and symptomatic arrhythmia recurrence, hospitalizations, and serious adverse events.
Main Results:
- Both RFA and cryoablation reduced overall arrhythmia recurrence compared to AADs.
- Radiofrequency ablation (RFA) significantly decreased hospitalizations, while cryoablation did not show a significant difference.
- Neither ablation method individually achieved statistically significant symptomatic recurrence reduction compared to AADs, but pooled ablation data showed benefit.
- Serious adverse event rates were comparable across all three treatment groups.
Conclusions:
- Cryoablation and RFA are safe and effective first-line therapies for PAF, offering an alternative to AADs.
- Radiofrequency ablation (RFA) appears to be the most effective strategy for reducing arrhythmia recurrence and hospitalizations in PAF patients.
More Related Videos
11:03Direct Pressure Monitoring Accurately Predicts Pulmonary Vein Occlusion During Cryoballoon Ablation
Published on: February 26, 2013
08:00Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter
Published on: June 15, 2015
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers